$EXEL

Eckhardt Sue Gail sold $492K of EXEL

Eckhardt Sue Gail sold 9,812 shares of EXELIXIS, INC. (EXEL) at $50.14 ($0.49M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Eckhardt Sue Gail
Published Jun 3, 2026, 10:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

The disclosure may slightly influence sentiment, but the presence of a pre-arranged 10b5-1 plan reduces interpretability as a new bearish fundamental view.

02

Market read

A routine 10b5-1 insider sale; potential for minor short-term sentiment noise rather than a catalyst.

03

What to watch

Director sales can be driven by diversification/tax planning; without changes in buying activity or new company fundamentals, the signal is limited.

Relevance 6/10Novelty 4/10Timing: Filed after-hours on 2026-06-03; sale executed 2026-06-01

Background

This is an SEC Form 4 insider transaction disclosure (director selling) for EXELIXIS, Inc.

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

Director Eckhardt Sue Gail sold 9,812 EXELIXIS shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Mild, short-lived negative-to-neutral sentiment impact; unlikely to drive a sustained move by itself.

Evidence & confidence

The filing is a routine 10b5-1 sale by a director with no accompanying operational or financial catalyst described.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None.

None.

Counterpoint

If the market overweights insider selling, the 10b5-1 structure suggests the trade may be mechanical rather than a bearish signal.

Key entities

  • EXELIXIS, INC.

    Company whose director insider sale was reported on SEC Form 4.

  • Eckhardt Sue Gail

    Director who executed an open-market sale under a Rule 10b5-1 plan.

Related articles

$EXELHigh

EXELIXIS, INC. (EXEL): Results of Operations and Financial Condition

EXELIXIS, INC. (EXEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 exel20260630exhibit991.htm EX-99.1 Document Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Andrew Peters SVP, Strategy & Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces

$EXELMed

EXEL Industries: Q3 2025-2026 revenue -18.7%

EXEL Industries reported Q3 FY2025-2026 revenue of €229.2m, down 18.7% year on year, or -18.0% at constant FX and scope, citing lower agricultural equipment volumes. Agricultural Spraying fell 17.1%, Sugar Beet Harvesting 35.6%, Leisure 14.2%, and Industry 16.7%. The company expects no significant cycle recovery before H2 FY2026-2027.

$EXELMedAI 9/10

If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

Exelixis reported Q1 2026 results that beat consensus, with non-GAAP EPS of $0.87 (up 14.02% vs. expectations) on revenue of $610.81 million (up 9.97% YoY). The company said CABOMETYX franchise revenue rose 12.5% YoY to $764 million and authorized a $750 million buyback through Dec. 31, 2027. Exelixis also has a Dec. 3, 2026 PDUFA decision for zanzalintinib in metastatic colorectal cancer.